001     130729
005     20240228143457.0
024 7 _ |a 10.1158/0008-5472.CAN-16-0932
|2 doi
024 7 _ |a pmid:27635044
|2 pmid
024 7 _ |a 0008-5472
|2 ISSN
024 7 _ |a 0099-7013
|2 ISSN
024 7 _ |a 0099-7374
|2 ISSN
024 7 _ |a 1538-7445
|2 ISSN
024 7 _ |a altmetric:12016730
|2 altmetric
037 _ _ |a DKFZ-2017-05807
041 _ _ |a eng
082 _ _ |a 610
100 1 _ |a Viski, Carmen
|b 0
245 _ _ |a Endosialin-Expressing Pericytes Promote Metastatic Dissemination.
260 _ _ |a Philadelphia, Pa.
|c 2016
|b AACR
336 7 _ |a article
|2 DRIVER
336 7 _ |a Output Types/Journal article
|2 DataCite
336 7 _ |a Journal Article
|b journal
|m journal
|0 PUB:(DE-HGF)16
|s 1521189872_1713
|2 PUB:(DE-HGF)
336 7 _ |a ARTICLE
|2 BibTeX
336 7 _ |a JOURNAL_ARTICLE
|2 ORCID
336 7 _ |a Journal Article
|0 0
|2 EndNote
520 _ _ |a Metastasis is a multistep process that is critically dependent on the interaction of metastasizing tumor cells with cells in the local microenvironment. Within this tumor stroma, vessel-associated pericytes and myofibroblasts share a number of traits, including the upregulated expression of the transmembrane receptor endosialin (CD248). Comparative experiments in wild-type and endosialin-deficient mice revealed that stromal endosialin does not affect primary tumor growth but strongly promotes spontaneous metastasis. Mechanistically, endosialin-expressing pericytes in the primary tumor facilitate distant site metastasis by promoting tumor cell intravasation in a cell contact-dependent manner, resulting in elevated numbers of circulating tumor cells. Corresponding to these preclinical experiments, in independent cohorts of primary human breast cancers, upregulated endosialin expression significantly correlates with increased metastasis and poorer patient survival. Together, the data demonstrate a critical role for endosialin-expressing primary tumor pericytes in mediating metastatic dissemination and identify endosialin as a promising therapeutic target in breast cancer. Cancer Res; 76(18); 5313-25. ©2016 AACR.
536 _ _ |a 311 - Signalling pathways, cell and tumor biology (POF3-311)
|0 G:(DE-HGF)POF3-311
|c POF3-311
|f POF III
|x 0
588 _ _ |a Dataset connected to CrossRef, PubMed,
650 _ 7 |a Antigens, CD
|2 NLM Chemicals
650 _ 7 |a Antigens, Neoplasm
|2 NLM Chemicals
650 _ 7 |a CD248 protein, human
|2 NLM Chemicals
650 _ 7 |a Neoplasm Proteins
|2 NLM Chemicals
650 _ 7 |a tumor endothelial marker 1, mouse
|2 NLM Chemicals
700 1 _ |a König, Courtney
|0 P:(DE-He78)5ef958977fa3c0658679b496419ce762
|b 1
|e First author
|u dkfz
700 1 _ |a Kijewska, Magdalena
|b 2
700 1 _ |a Mogler, Carolin
|0 P:(DE-He78)18e5b355e4a312d2065b1ae2a9d47654
|b 3
|u dkfz
700 1 _ |a Isacke, Clare M
|b 4
700 1 _ |a Augustin, Hellmut
|0 P:(DE-He78)2e92d0ae281932fc7347d819fec36b0b
|b 5
|e Last author
|u dkfz
773 _ _ |a 10.1158/0008-5472.CAN-16-0932
|g Vol. 76, no. 18, p. 5313 - 5325
|0 PERI:(DE-600)2036785-5
|n 18
|p 5313 - 5325
|t Cancer research
|v 76
|y 2016
|x 1538-7445
909 C O |o oai:inrepo02.dkfz.de:130729
|p VDB
910 1 _ |a Deutsches Krebsforschungszentrum
|0 I:(DE-588b)2036810-0
|k DKFZ
|b 1
|6 P:(DE-He78)5ef958977fa3c0658679b496419ce762
910 1 _ |a Deutsches Krebsforschungszentrum
|0 I:(DE-588b)2036810-0
|k DKFZ
|b 3
|6 P:(DE-He78)18e5b355e4a312d2065b1ae2a9d47654
910 1 _ |a Deutsches Krebsforschungszentrum
|0 I:(DE-588b)2036810-0
|k DKFZ
|b 5
|6 P:(DE-He78)2e92d0ae281932fc7347d819fec36b0b
913 1 _ |a DE-HGF
|l Krebsforschung
|1 G:(DE-HGF)POF3-310
|0 G:(DE-HGF)POF3-311
|2 G:(DE-HGF)POF3-300
|v Signalling pathways, cell and tumor biology
|x 0
|4 G:(DE-HGF)POF
|3 G:(DE-HGF)POF3
|b Gesundheit
914 1 _ |y 2016
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0300
|2 StatID
|b Medline
915 _ _ |a JCR
|0 StatID:(DE-HGF)0100
|2 StatID
|b CANCER RES : 2015
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0200
|2 StatID
|b SCOPUS
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0310
|2 StatID
|b NCBI Molecular Biology Database
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0600
|2 StatID
|b Ebsco Academic Search
915 _ _ |a Peer Review
|0 StatID:(DE-HGF)0030
|2 StatID
|b ASC
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0199
|2 StatID
|b Thomson Reuters Master Journal List
915 _ _ |a WoS
|0 StatID:(DE-HGF)0110
|2 StatID
|b Science Citation Index
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0150
|2 StatID
|b Web of Science Core Collection
915 _ _ |a WoS
|0 StatID:(DE-HGF)0111
|2 StatID
|b Science Citation Index Expanded
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)1110
|2 StatID
|b Current Contents - Clinical Medicine
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)1030
|2 StatID
|b Current Contents - Life Sciences
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)1050
|2 StatID
|b BIOSIS Previews
915 _ _ |a IF >= 5
|0 StatID:(DE-HGF)9905
|2 StatID
|b CANCER RES : 2015
920 1 _ |0 I:(DE-He78)A190-20160331
|k A190
|l Vaskuläre Onkologie und Metastasierung
|x 0
920 1 _ |0 I:(DE-He78)L101-20160331
|k L101
|l DKTK Heidelberg
|x 1
980 _ _ |a journal
980 _ _ |a VDB
980 _ _ |a I:(DE-He78)A190-20160331
980 _ _ |a I:(DE-He78)L101-20160331
980 _ _ |a UNRESTRICTED


LibraryCollectionCLSMajorCLSMinorLanguageAuthor
Marc 21